20/20 is a revenue stage company that develops and commercializes biomarker based diagnostic tests and algorithms to improve outcomes for cancer patients. Our a blood test for the early detection of lung cancer has been successfully test marketed regionally and is now ready for a nationwide roll-out. We have other cancer tests in the pipeline and stable revenues and profits from a patented biosecurity product sold to the emergency responders.